newsfilter
← Latest News
GlobeNewswire·

Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint under evaluation to